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Abstract: COVID-19 emerged in December 2019 in China, and since then, has disrupted 
global public health and changed economic paradigms. In dealing with the new 
Coronavirus, SARS-CoV-2, the world has not faced such extreme global fragility since the 
“Spanish flu” pandemic in 1918. Researchers globally are dedicating efforts to the search 
for an effective treatment for COVID-19. Drugs already used in a clinical setting for other 
pathologies have been tested as a new therapeutic approach against SARS-CoV-2, setting 
off a frenzy over the preliminary data of different studies. This work aims to compile and 
discuss the data published thus far. Despite the potential effects of some antivirals and 
antiparasitic against COVID-19, clinical studies must confirm real effectiveness. However, 
non-pharmacological approaches have proven to be the most efficient strategy to date.
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INTRODUCTION
The world is currently facing a pandemic caused 
by a virus in the Coronaviridae family, namely 
SARS-CoV-2, disrupting global public health and 
world economies. COVID-19, the disease caused 
by SARS-CoV-2 (WHO, 2020a), is a viral infection 
that affects the respiratory system, resulting in 
respiratory syndrome. COVID-19 is considered 
the most serious of pandemics since 1918 
when the “Spanish flu” (H1N1) (Al Hasan et al. 
2020, Zand & Wang 2020) emerged. The search 
for effective treatment and vaccine is frenzied, 
mobilizing research groups worldwide. Currently, 
there are still no drugs or vaccines proven to 
treat or prevent infection caused by SARS-CoV-2 
(CDC 2020). However, numerous studies are 
currently being conducted (CDC 2020, NIH 2020).
The dramatic story of COVID-19 began 
at the end of December 2019, when a new 
species of the virus from the Coronaviridae 
family emerged in the city of Wuhan, China (Al 
Hasan et al. 2020, WHO 2020b). Initially, the 
outbreak demonstrated similar characteristics 
and symptoms to the Severe Acute Respiratory 
Syndrome-related Coronavirus (SARS). Initially, 
the World Health Organization (WHO) gave the 
virus the nomenclature 2019-nCoV, but it was 
later renamed SARS-CoV-2 by the International 
Committee on Viruses Taxonomy (Gorbalenya 
et al. 2020). Since January 21, 2020, WHO reports 
daily on the spread of the disease (Millán-Oñate 
et al. 2020, WHO 2020a)
CORONAVIRUS BIOLOGY 
Coronaviridae virus family is enveloped, positive-
sense single-stranded RNA included in group 
IV of the Baltimore classification (Gorbalenya 
et al. 2020, Arakawa & Morita 2019, Reid et al. 
2015). The SARS-CoV-2 virus particles are round 
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or oval, with a diameter of about 60–140 nm. The 
sequence analysis demonstrates that the novel 
coronavirus belongs to Betacoronavirus Lineage 
β, Sarbecovirus, as SARS-CoV and MERS-CoV are 
included (Zhu et al. 2020a). 
After entering the cells, the coronavirus 
uses host cell protein translation machinery 
to produce the viral polyprotein that needs 
to be cleaved into effector proteins.  The 
viral proteases coronaviral principal protease 
(3CLpro) and papain-like protease (PLpro) are 
responsible for the cleavage (Báez-Santos et al. 
2015). The viral genome also encodes a variety of 
nonstructural proteins such as RNA-dependent 
RNA polymerase (RdRp) (Ziebuhr et al. 2000).
The SARS-CoV-2 genome size varies from 
29.8 kb to 29.9 kb, and share 96% identical at 
the whole-genome level to a bat coronavirus, 
and 79.6% sequence identity to SARS-CoV (Zhou 
et al. 2020a). Its genome structure followed the 
specific gene characteristics (Lu et al. 2020). 
The 5’ region corresponds to approximately 
two-thirds of the genome and holds orf1ab 
encoding orf1a polyproteins. The 3’ consists of 
genes encoding structural proteins, including 
surface, envelope, membrane, and nucleocapsid 
proteins. Besides, the SARS-CoV-2 contains six 
accessory proteins, encoded by ORF3a, ORF6, 
ORF7a, ORF7b, and ORF8 genes (Khailany et al. 
2020, Li et al. 2005). 
In general, viral infections follow a well-
established pattern, in which viruses depend on 
host-cells’ biosynthetic machinery to replicate 
its genome and generate descending virus 
particles (Romero-Brey & Bartenschlager 2014). 
Therefore, viruses are mandatory intracellular 
parasites (Paul & Bartenschlager 2013, Romero-
Brey & Bartenschlager 2016). Inside the 
cytoplasm, at the onset of infection, the host-
cell rises to produce viral proteins instead of 
protein synthesis, which is interrupted by the 
viral proteases. This step is essential in starting 
the process of viral-translating genetic material 
(Modrow et al. 2013). These viral lifecycle steps 
provide potential targets for drug therapy.
The virus infection commonly occurs 
between the interaction of viral surface 
molecules and the host-cell membrane. A host 
cell receptor mediates the SARS-CoV-2 entry into 
cells, as this hypothesis has already been tested 
for SARS-CoV (Xu et al. 2020, Zhou et al. 2020a). 
Initially, SARS-CoV was thought to enter host 
cells through membrane fusion (Ng et al. 2003, 
Qinfen et al. 2004). However, subsequent studies 
have shown that the SARS-CoV entry process is 
by receptor-mediated membrane endocytosis, 
and that pH also plays a role (Simmons et al. 
2005, Wang et al. 2008). 
Observations have shown the SARS-CoV 
infects ciliated bronchial epithelial cells and 
type-II pneumocytes through Angiotensin-
Converting Enzyme 2 (ACE2) as a receptor (Qian 
et al. 2013). Also, data supports that SARS-
CoV uses its Spike glycoprotein (S) to bind its 
receptor and mediate membrane fusion and 
virus entry. The trimeric S protein is about 
180 kDa and contains two subunits, S1 and S2, 
mediating attachment and membrane fusion, 
respectively. Nonetheless, SARS-CoV-2 spike (S) 
proteins share about 76% and 97% of amino acid 
identities with SARS-CoV and MERS, respectively 
(Zhou et al. 2020a). It has been shown the SARS-
CoV-2 envelope spike (S) protein mediates 
receptor binding and membrane fusion, and 
it is crucial for determining host tropism and 
transmission capability (Lu et al. 2020). 
The S protein of SARS-CoV-2 seems to 
be more adapted for binding to the human 
receptor ACE2 (Andersen et al. 2020). Another 
host cell receptor, the type 2 transmembrane 
serine protease, TMPRSS2, participates in the 
infection process facilitating cell entry via the 
S protein (Hoffmann et al. 2020a). Inside the 
host cell, viral polyproteins are synthesized that 
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encode for the replicase-transcriptase complex. 
The virus then synthesizes RNA via its RNA-
dependent RNA polymerase. Structural proteins 
are synthesized leading to the completion of 
assembly and release of viral particles (Sanders 
et al. 2020). 
In addition to the replication process, viruses 
can induce strong antiviral responses in the host 
organism, representing a “hostility” between the 
virus and host to gain control over the resources 
of the infected cell (Nagy & Pogany 2011) and 
when not neutralized, viruses tend to win the 
battle. For example, recently, studies have shown 
the COVID-19 disease severity triggers a “cytokine 
storm syndromes”, a hyperinflammatory 
syndrome characterized by a fulminant and 
fatal hypercytokinemia (Mehta et al. 2020). This 
“cytokine storm syndromes” is characterized by 
increased interleukin (IL)-2, IL-7, granulocyte-
colony stimulating factor, interferon-γ inducible 
protein 10, monocyte chemoattractant protein 
1, macrophage inflammatory protein 1-α, and 
tumor necrosis factor-α (Huang et al. 2020). 
This pathophysiological phenotype of COVID-19 
is an additional aggravation of infection and 
development of the disease.
FEASIBLE THERAPEUTIC APPROACHES
From data on other coronaviruses, such as 
SARS-CoV infection and the viral replication 
process, as well as drug tests with possible 
treatment results, start a “gold rush” to look for 
an available ligand or molecule that may affect 
SARS-CoV-2.
Thus, this review compiled the principal 
findings from the recent data.  We have grouped 
the pivotal drugs studied at the moment 
with a therapeutic alternative to COVID-19. 
The molecular structures of these drugs are 
presented in figure 1. In order to make the 
discussion articulate, we grouped the drugs 
according to their mechanisms of action, or 
previously described function.




Figure 1. The molecular 
structure of the primary 
drugs as a therapeutic 
approach to COVID-19. 
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ANTIVIRALS 
Antivirals belong to the pharmacological class 
responsible for inhibiting the action of viruses 
in the body. These drugs are classified according 
to their action mechanisms (Hardman & Limbird 
2005, Ison 2017). Standing out among these 
mechanisms are the following: the deactivation 
of virions (virus particles that appear after the 
viral replication process that are capable of 
infecting new cells), blocking the virus from 
binding to the cell receptor and inhibiting 
processes related to its replication, such as 
protease, integrase, and/or reverse transcriptase 
(Ison 2017).
Protease inhibitors
Widely used in the antiretroviral treatment of 
HIV, these inhibitors interfere with the synthesis 
of host-cell proteins and consequently 
interrupt the viral replication process. Ritonavir, 
Saquinavir, Fosamprenavir, and Lopinavir are 
examples of protease inhibitors (Mitsuyasu et al. 
1998, Tenore & Ferreira 2009, Lv et al. 2015, Midde 
et al. 2016, Pokorná et al. 2009).
Protease is a key enzyme in coronavirus 
polyprotein processing, and drugs such as 
Lopinavir and/ Ritonavir could be an option 
playing anti-coronavirus activity (Yavuz  & Ünal 
2020).
Lopinavir, Ritonavir 
In 2003, after the appearance of SARS, the 
combination of Lopinavir and Ritonavir, two 
antivirals of the protease inhibitor class 
used in the treatment cocktail of HIV-type 1, 
demonstrated inhibitory activity against SARS-
CoV (Chen et al. 2004, Chu et al. 2004, Wu et al. 
2004). The combination of Lopinavir + Ritonavir 
increases the plasma half-life of drugs through 
inhibiting cytochrome P450, which results in 
improved action time (Kirby et al. 2011).
Based on the findings for Lopinavir 
+ Ritonavir against SARS-CoV, a group of 
researchers conducted a randomized, open, and 
controlled clinical trial on adult hospitalized 
patients with a confirmed SARS-CoV-2 infection. 
The data from this study was recently published 
in the renowned The New England Journal of 
Medicine. In the study, patients were divided 
into two groups in a 1:1 ratio. One group received 
treatment with Lopinavir (400 mg) + Ritonavir 
(100 mg) twice daily for 14 days in addition to 
standard treatment. The control group received 
only standard treatment (Cao et al. 2020).
The most common adverse events 
observed in the Lopinavir-Ritonavir group were 
gastrointestinal changes. In contrast, the control 
group, which received standard treatment, 
evolved with more serious adverse events such 
as respiratory failure, acute renal failure, and 
secondary infection (Cao et al. 2020).
Although the antiviral treatment did not 
differ significantly from the standard treatment 
in terms of clinical improvement (risk rate 
for clinical improvement 1.24, 95% confidence 
interval [CI], 0.90 to 1.72), the index mortality 
over 28 days was lower in the group treated 
with Lopinavir + Ritonavir (19.2% vs. 25.0%, with 
a 95% confidence interval, 17.3% to 5.7%) (Cao 
et al. 2020). Another important observation of 
the study was that a low number of patients 
in the Lopinavir + Ritonavir group had severe 
complications (acute renal failure and secondary 
infection) and less need for non-invasive or 
invasive mechanical ventilation than the group 
that received only standard treatment. However, 
researchers are careful with these findings and 
suggest additional studies be conducted before 
affirming that the combination of these antivirals 
is responsible for improving the clinical picture 
and changing the course of the disease (Cao et 
al. 2020).
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In another clinical study, a group of Korean 
doctors with experience in treating patients 
infected by SARS-CoV-2 suggested that antiviral 
drugs are not recommended for use in young, 
healthy patients with mild symptoms and 
without underlying comorbid conditions (Smith 
& Prosser 2020). In this study, the researchers 
recommended that the following treatment be 
aimed at elderly patients or those with underlying 
conditions and severe symptoms. The treatment 
combines the following medications: Lopinavir 
(400 mg), Ritonavir 100 mg or Chloroquine (500 
mg), or Hydroxychloroquine (400 mg) (Gao et al. 
2020, Physicians work out treatment guidelines 
for coronavirus - Korea Biomedical Review 2020, 
Smith & Prosser 2020).
Nucleotide Analogs
This class is applied as broad-spectrum antivirals 
and may inhibit the RNA polymerase of viruses 
preventing its replication (Xu et al. 2020a). An 
animal model study (mice) testing Remdesivir, 
for example, demonstrated its inhibitory effect 
on Middle-East respiratory syndrome (MERS) 
(Agostini et al. 2018) and SARS-CoV (Sheahan et 
al. 2017).
Remdesivir
Remdesivir is an adenosine analog that 
is incorporated into nascent RNA chains 
and this step results in RNA premature 
termination (Warren et al. 2016). Remdesivir is 
a phosphoramidate prodrug of an adenosine 
C-nucleoside metabolized into its active 
form, GS-441524. Remdesivir delays the chain 
termination and blocking the proofreading 
function by exoribonuclease (Figure 2), an 
enzyme responsible for RNA degradation, by 
removing terminal nucleotides from both ends 
(5 “or 3”) (Agostini et al. 2018, Siegel et al. 2017).
A broad-spectrum antiv iral  agent 
synthesized and developed by Gilead Sciences 
in 2017 as a treatment for Ebola virus infection 
(Siegel et al. 2017). Also, Remdesivir has shown 
promising results for a wide variety of virus 
infections whose genetic material is RNA 
(Martinez 2020). It has demonstrated antiviral 
activity against SARS and MERS (Wang et al. 
2020).
With promising effects previously known 
against Coronaviruses, a group conducted 
in vitro tests combining Remdesivir and 
Chloroquine against SARS-CoV-2. The in-vitro 
study evaluated the combined activity of these 
drugs using the Vero E6 cell model (ATC-1586). 
Tests were performed to measure cytotoxicity 
and the rate of viral infection (Wang et al. 2020). 
The data demonstrated that the combination 
of these drugs potentially blocked SARS-CoV-2 
infection at a low micromolar concentration 
(Wang et al. 2020). Furthermore, the same 
research group claimed that Remdesivir also 
effectively inhibited SARS-CoV-2 infection in a 
human cell line (human liver cancer Huh-7 cells) 
(Wang et al. 2020). 
From these encouraging results, some 
groups have started clinical studies. Currently, 
a clinical trial testing the effectiveness of 
Remdesivir in patients infected with SARS-CoV-2 
is being conducted in China (Smith & Prosser 
2020). More recently, Remdesivir was evaluated 
in a compassionate study in hospitalized 
patients diagnosed with COVID-19. The patients 
presented an oxygen saturation of 94% or less, 
breathing in the environment or with the aid 
of respirators. For 10 days, Remdesivir was 
administered in the following dosages: 200 mg 
on the first day and 100 mg on the next 9 days, 
from January 25 to March 7, 2020 (Grein et al. 
2020).
A total of 53 patients, from different regions 
such as North America (USA and Canada), Europe 
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and Japan, followed in the study. Interestingly, 
the data showed that of the 53 hospitalized 
patients diagnosed with Covid-19 with severe 
symptoms, treated with compassionate use 
of Remdesivir, 36 (68%) achieved clinical 
improvement. However, even with promising 
results, the authors are cautious and claim that 
randomized clinical trials are needed, which are 
currently in progress (Grein et al. 2020).
Favipiravir
Favipiravir (Avigan) has been developed by 
Fujifilm Toyama Chemical in 2014 in Japan for the 
treatment of avian influenza or novel influenza 
resistant to neuraminidase inhibitors. Favipiravir 
(RNA polymerase inhibitor) is a guanine analog 
in the same class of the Remdesivir and as 
its antiviral activity similar this drug could 
potentially exhibit effects against SARS-CoV-2 
(Furuta et al. 2017).
Favipiravir initially acts as a prodrug entering 
cells through endocytosis, and then after 
phosphoribosylation and phosphorylation, it is 
converted into an active favipiravir ribofuranosyl 
phosphates (Furuta et al. 2013). The antiviral 
activity is exhibited through selectively targeting 
the conservative catalytic domain of RNA-
dependent RNA polymerase (RdRp), interrupting 
the nucleotide incorporation process during viral 
RNA replication (Furuta et al. 2017). Favipiravir 
demonstrated 100% effectiveness in protecting 
mice against the Ebola virus, although its EC50 
value in Vero E6 cells was high (Oestereich et al. 
2014). Favipiravir has been used in the treatment 
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Figure 2. Therapeutic approaches in clinical test for COVID-19. SARS-CoV-2 model of infection and Remdesivir, 
Chloroquine and Hydroxychloroquine mechanisms elucidated.
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of infectious diseases caused by RNA viruses 





A vigorous discussion about the use 
o f  Ch lo roqu ine  and  i t s  de r i va t i ve 
Hydroxychloroquine has raised the spirits 
about practical therapeutic approaches for 
COVID-19 treatment.  Scientific evidence, while 
impressive, raises many questions. In this 
fashion, we intend to discuss and present 
updated data on this topic.
Chloroquine (CQ) and hydroxychloroquine 
(HCQ) are aminoquinolines with known anti-
inflammatory (Ornstein & Sperber 1996) and 
antimalarial properties (Ben-Zvi et al. 2012, 
Wellems & Plowe 2001), have recently emerged 
as “a promise” in the treatment of COVID-19 
(Colson et al. 2020, Cortegiani et al. 2020). 
Chloroquine was initially used to treat 
Plasmodium sp., a malaria disease agent 
(Aronson 2016, Homewood et al. 1972, Wellems 
& Plowe 2001). However, because of its high 
toxicity and the development of Plasmodium 
resistance to the drug (Krogstad et al. 1987), 
the need to develop new molecules emerged. 
Hydroxychloroquine sulfate is a derivative of 
Chloroquine and was first synthesized in 1946 by 
the introduction of a hydroxyl group, and proved 
to be less toxic than Chloroquine (McChesney 
1983) (Figure 1). HCQ is widely employed to 
treat autoimmune diseases such as systemic 
lupus erythematosus and rheumatoid arthritis 
(Rainsford et al. 2015). Its availability, proven 
safety record, and relatively low cost have 
rendered it a considerable alternative to large-
scale treatment.
In humans, the effect of both Chloroquine 
and Hydroxychloroquine is well described. For 
example, it is understood that oral absorption 
is efficient. In animal tests, both drugs share 
similar standards of pharmacokinetics and 
bioavailability, with higher concentrations in the 
liver, spleen, kidney, and lung, peaking between 
200–700 times greater than those of plasma 
(Laaksonen et al. 1974, Popert 1976). 
 CQ and HCQ are able to modulate 
some cellular functions involved in immune 
activation such as inhibition of MHC class 
II expression, CD154 expression by T cells, 
cytokines IL-1, IFNα and TNFα, which can 
protect against cytokine-mediated, GMP-AMP 
(cGAMP) synthase (cGAS) activity, lysosomes 
and autophagosomes changing local pH 
concentrations (Schrezenmeier & Dörner 2020). 
Besides, both CQ and HCQ are weak bases known 
to raise the pH to reinforce the hypothesis to 
interfere in acidic intracellular organelles such 
as endosomes/lysosomes, which are essential 
for membrane fusion (Krogstad & Schlesinger 
1987). This mechanism is proposed for both 
drugs acting as the COVID-19 therapeutic 
approach. 
According to these data, some studies 
tested CQ and HCQ against SARS-CoV-2 and 
have demonstrated these drugs can reasonably 
inhibit some virus steps of infection in a safe 
dosage (Liu et al. 2020). It was proposed that 
CQ and HCQ could block viral entry into cells 
by inhibiting glycosylation of host receptors, 
proteolytic processing (Figure 2), and endosomal 
acidification  (Savarino et al. 2006, Vincent et al. 
2005, Zhou et al. 2020b). 
Chloroquine, in vitro, was able to inhibit 
SARS-CoV-2 with a half-maximal concentration 
(EC50) in the low micromolar range. Culture tests 
on Vero E6 cells with 50% and 90% effective 
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concentrations (EC50 and EC90 values) of 1.13 
μM and 6.90 μM, respectively (Wang et al. 2020) 
were done. Also, reported mechanisms suggest 
a blockage of the transport of SARS-CoV-2 from 
endosomes to lysosomes. This step seems to be 
an important process for the release of the viral 
genome. Assuming that the maturation of the 
endosome may be blocked in the intermediate 
stages of endocytosis, this will result in the 
failure of the additional transport of virions to 
the final release site (Liu et al. 2020).
A systematic review of the use of Chloroquine 
for the treatment of COVID-19 affirmed that a 
sufficient rationale exists for clinical use. This 
is in addition to preclinical evidence of efficacy 
and safety evidence based on the prolonged 
use of the drug for other diseases. However, 
the researchers emphasize that safety data and 
high-quality clinical trial data from clinical use 
for COVID-19 are urgently needed, which should 
be monitored or ethically approved for clinical 
trials (Cortegiani et al. 2020).
Since the promising in vitro data, groups 
have started clinical studies with CQ and HCQ in 
COVID-19 positive patients. A recent open-label 
nonrandomized French study of 36 patients 
(20 in the hydroxychloroquine group and 16 in 
the control group) reported improved virologic 
clearance. Oral hydroxychloroquine sulfate 200 
mg was administered three times per day for ten 
days. The endpoint was virological clearance at 
day-6 post-inclusion, also secondary outcomes 
were virological clearance overtime during 
the study period, clinical follow-up (body 
temperature, respiratory rate, long of stay at 
hospital and mortality), and occurrence of side-
effects. The authors tested the combination 
azithromycin +  hydroxychloroquine, and they 
reported that the addition in 6 patients resulted 
in superior viral clearance (6/6, 100%) compared 
with hydroxychloroquine monotherapy (8/14, 
57%) (Gautret et al. 2020).
A recent observational clinical study (Funded 
by the National Institutes of Health) published 
on May 7, in The New England Journal (Geleris et 
al. 2020) followed 1376 patients, during a median 
follow-up of 22.5 days, 811 (58.9%) received 
hydroxychloroquine (600 mg twice on day 1, then 
400 mg daily for a median of 5 days), 45.8% of 
the patients were treated within 24 hours after 
presentation to the emergency department, and 
85.9% within 48 hours. The authors affirmed 
the hydroxychloroquine administration was not 
associated with either a greatly lowered or an 
increased risk of the composite endpoint of 
intubation or death. Also, the authors conclude 
to be necessary randomized, controlled trials of 
hydroxychloroquine in patients with COVID-19 
(Geleris et al. 2020).
 A retrospective multicenter cohort study of 
patients from a random sample published more 
recently, rated the use of HCQ alone or with the 
interaction of Azithromycin in the metropolitan 
area of the state of New York - USA. In all, 1438 
patients diagnosed with COVID-19, middle-
aged men, aged 63, received only HCQ or both 
drugs, had more significant complications 
than patients who did not receive this therapy. 
The authors conclude the treatment with 
hydroxychloroquine, azithromycin, or both, 
compared with neither treatment, was not 
significantly associated with differences in in-
hospital mortality. However, the authors also list 
a number of limitations of this observational 
study, they emphasize the need for clinical trials 
to provide definitive causal evidence of the 
effect of hydroxychloroquine and azithromycin 
on mortality, while also providing an opportunity 
to more finely control baseline patient severity 
and the dose and timing of drug administration 
(Rosenberg et al. 2020).
Additionally, it is necessary to point 
out that even though Chloroquine and 
Hydroxychloroquine are relatively well-tolerated 
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since the long time have been using for malaria 
treatment, studies warn of the risks. About 10% 
of the patients using both agents can present 
rare and severe adverse effects, including QTc 
prolongation, hypoglycemia, neuropsychiatric 
effects, and retinopathy (Sanders et al. 2020).
Ultimately, a discussion on the emerging 
use of Chloroquine or its derivative 
Hydroxychloroquine is undoubtedly necessary. 
Scientific evidence to ensure that this treatment 
proposal is genuinely compelling is currently 
insufficient.
In Brazil, the National Health Surveillance 
Agency (ANVISA) first declared that although 
promising, no conclusive studies prove the 
effective use of these drugs in the treatment 
of COVID-19 (ANVISA 2020a). More recently, 
ANVISA authorized a study that will apply 
Hydroxychloroquine in the treatment of patients 
with COVID-19 (ANVISA 2020b). 
Brazilian healthy agency, ANVISA, has 
consent (ANVISA 2020b) involves two studies: 
a) An open, controlled study of the use of 
Hydroxychloroquine and Azithromycin to prevent 
complications in patients infected with COVID-19: 
a randomized and controlled study (mild to 
moderate cases). b) Evaluation of the safety 
and clinical efficacy of Hydroxychloroquine 
associated with Azithromycin in patients with 
pneumonia caused by infection with the Sars-
CoV-2 virus (critically ill patients).
Antibiotic
Azithromycin
Azithromycin is an antibiotic applied for the 
treatment of several different types of infections 
caused by susceptible bacteria (Perter et al. 
1992). Azithromycin binds to the 50S subunit 
of the bacterial ribosome, inhibiting mRNA 
translation  (Bulkley et al. 2010, Tu et al. 2005).
The use of Azithromycin together with other 
drugs has been successfully applied in the clinic 
for the treatment of viruses and to prevent 
severe respiratory tract infections for patients 
suffering from viral infection (Madrid et al. 2015, 
Retallack et al. 2016). As discussed before, the 
positive data for the use of its azithromycin 
along with hydroxychloroquine, in a COVID-19 
clinical trial have been proposed (Gautret et al. 
2020). In an open-label non-randomized study 
in France hydroxychloroquine + azithromycin 
presented with the highest virologic cure rate 
following 6-day treatment (Gautret et al. 2020). 
However, other studies affirm the data 
presented to date are insufficient to evaluate 
possible clinical benefits of azithromycin 
in patients with COVID-19 and repeated the 
experiments found patients had significant 
comorbidities (Molina et al. 2020).
Nitazoxanide
Nitazoxanide (Fig. 1), an antiprotozoal, is an 
orally active nitrothiazolysalicylamide and 
antiviral prodrug that is converted rapidly to the 
active metabolites tizoxanide and nitazoxanide 
conjugates and unlike metronidazole (Rang et 
al. 2007, Rossignol 2016). Similarly, nitazoxanide 
is also known to potentiate interferon-alfa and 
interferon-beta production and it has been 
previously shown to exhibit an in vitro activity 
against MERS-CoV and other coronaviruses 
(Rossignol 2016).
Nitazoxanide is hypothesized as a likely 
therapeutic approach and could have antiviral 
potential against Sars-CoV-2, as it works by 
interfering with host-regulated pathways in 
viral replication, amplifying the detection of 
cytoplasmic RNA and Interferon type 1. Some 
author suggests that nitazoxanide/azithromycin 
combination could have a potential that should 
be properly tested in clinical trials including 
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randomized controlled trials (Kelleni 2020, 
Şimşek & Ünal 2020).
Serine protease inhibitor 
Nafamostat
Nafamostat, a serine protease inhibitor that 
works as an anticoagulant, has demonstrated 
satisfactory results in inhibiting the action of 
MERS-CoV and has been shown to be effective 
against SARS-CoV-2 infection, preventing 
membrane fusion (Wang et al. 2020).
Nafamostat mesylate inhibits TMPRSS2-
dependent host cell entry of MERS-CoV 
(Yamamoto et al. 2016), and TMPRSS2 is 
responsible for cleaving and activate Sars-Cov-2 
S protein. However, the use of this anticoagulant 
in the treatment for COVID-19 is in a clinical trial, 
and the exact concentration of the compound 
to inhibit viral replication is not yet clear. In 
the deficiency of this information, other serial 
protease inhibitors were tested to inhibit 
the entry of Sars-Cov-2 into the cell, such as 
Naphthostat mesylate, which is already used for 
human use in Japan and the fact that this drug 
inhibits the action of TMPRSS2 in the host cell 
for infections caused by MERS-CoV (Hoffmann 
et al. 2020b).
Nafamostat has FDA approval (unrelated 
to infections caused by coronavirus), and has 
been shown to inhibit the entry of Sars-Cov-2 
mediated by protein S into the host cell with 
greater efficiency than Naphthostat mesylate, 
thus being considered the best option for the 
treatment of COVID-19 concerning the other 
serine protease inhibitors due to its higher 
safety and antiviral activity (Hoffmann et al. 
2020b).
Non-pharmacological approaches
An epidemiological modeling study published at 
Imperial College (Impact of non-pharmaceutical 
interventions (NPIs) to reduce COVID-19 mortality 
and healthcare demand) has been transforming 
the world paradigm regarding understanding 
adopted measures. The study demonstrates 
that non-pharmacological approaches can have 
a much more efficient impact on controlling the 
spread of COVID-19, thus preventing the collapse 
of the health system (Ferguson et al. 2020). 
The proposed strategies to contain the 
population are: mitigation (which aims to 
reduce the demand for health care by protecting 
at-risk groups), and suppression (which aims to 
reverse the growth of the epidemic, reducing the 
number of cases to low levels, and maintaining 
this situation indefinitely) (Ferguson et al. 2020). 
According to this epidemiological modeling, 
without actions of containment, the number of 
deaths in the United States, for example, could 
a total of 2.2 million people.
However, the authors emphasize that it 
is not certain that suppression will succeed 
in the long term, and that no public health 
interventions with such disruptive effects on 
society have been tried before for such a long 
period (Ferguson et al. 2020). 
CONCLUSIONS
There is some scientific evidence of particular 
drugs such as antivirals, antiparasitic, and 
anticoagulants as approaches for treatment 
Coronavirus infections (Chu et al. 2004, Martinez 
2020, Wu et al. 2004). Currently, more than 300 
active clinical treatment trials are advancing. 
Unfortunately, until now, there is no evidence 
from randomized clinical trials with substantial 
therapy improves outcomes in COVID-19 
patients. No clinical trial data are supporting 
any prophylactic therapy. 
The current COVID-19 pandemic has caused 
hopelessness in the population, resulting in an 
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overwhelming spread of panic and economic 
imbalance in affected regions (Anderson et al. 
2020, Atkeson 2020, Ruiz Estrada 2020). Thus, the 
population yearns for a practical therapeutic 
approach.
It must be emphasized that more clinical 
tests still need to be performed to ensure the 
use and effectiveness of the drugs reviewed in 
this work in the treatment and prevention of 
COVID-19 (Cao et al. 2020). The world is alarmed 
and confused; however, science is based 
on evidence generated through a rigorous 
methodology, which requires randomized 
studies for clinical application. Regrettably, 
these studies require time to be conducted, 
and results for the general population may 
differ from those initially evidenced in in-vitro 
investigations or in specific populations.
Thus, researchers, health professionals, and 
government representatives must discuss the 
best way to face this public health crisis. The 
most reliable way thus far adopted in various 
countries is preventing the virus from spreading 
by containing the population and enforcing 
mitigation. However, the appeal for the use of 
drugs with probable effectiveness, even with 
limited studies, is remarkably strong.
An important aspect to consider is that 
the medications currently proposed have the 
advantage of already being used as therapeutic 
options for other diseases. Consequently, these 
are approved for the treatment of humans, and 
their effects are well known. However, the results 
of more refined studies on safe and effective 
drug options will guarantee patients a truly safe 
treatment with the possibility of cure and/or 
prevention. Today, with the data thus far, this 
cannot be guaranteed.
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